The company has great management...that is why they have made great progress in the past 4 years. King and Garnick are very able honest men. Some drug combinations are better than others. Some cancer indications are tougher than others. But biopharms point about Bavi playing well with others is important. This means it works well with most current SOC and will work well with the coming generation of drugs. I can see Bavi being used with combination treatments in lung, breast, pancreatic, liver....indeed with ALL solid tumours...and with the new generation of immunotherapeutic drugs and vaccines. And we are very near the use of second generation BAVI. And all because of the great science of Dr. Thorpe and the great management of King and Garnick. Things are going well...the share price will follow!